/term/bs-deferred-policy-acquisition-costs/XKRX:217950 Pharmaresearch Bio Co (XKRX:217950) Deferred Policy Acquisi
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaresearch Bio Co Ltd (XKRX:217950) » Definitions » Deferred Policy Acquisition Costs

Pharmaresearch Bio Co (XKRX:217950) Deferred Policy Acquisition Costs


View and export this data going back to 2015. Start your Free Trial

What is Pharmaresearch Bio Co Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.

Pharmaresearch Bio Co (XKRX:217950) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaresearch Bio Co Ltd (XKRX:217950) » Definitions » Deferred Policy Acquisition Costs
Comparable Companies
XKRX:341170 XKRX:304360 XKRX:378800 XKRX:352770 XKRX:086820 XKRX:244460 XKRX:263050 XKRX:308080 XKRX:288330 XKRX:216400 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
641-3, Saimdang-ro, Gangwon-do, Gangneung-si, KOR, 13494
Website
http://www.pr-bio.co.kr
Pharmaresearch Bio Co Ltd is a Korea-based biopharmaceutical company. The company is engaged in the research and development, manufacturing, sale, and marketing of biopharmaceutical products. Its product is ReNTox Injections, and Clostridium Botulinum Toxin type A is in pipeline.